Opthea Ltd
ASX:OPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Opthea Ltd
Total Equity
Opthea Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Opthea Ltd
ASX:OPT
|
Total Equity
$33.7m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
6%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Equity
$574.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
CSL Ltd
ASX:CSL
|
Total Equity
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Equity
AU$23.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Equity
AU$415.4m
|
CAGR 3-Years
73%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Equity
AU$147.2m
|
CAGR 3-Years
87%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Opthea Ltd
Glance View
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing and commercializing therapies primarily for eye diseases. The firm's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The firm's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. The company has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.
See Also
What is Opthea Ltd's Total Equity?
Total Equity
33.7m
USD
Based on the financial report for Dec 31, 2025, Opthea Ltd's Total Equity amounts to 33.7m USD.
What is Opthea Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
6%
The average annual Total Equity growth rates for Opthea Ltd have been -16% over the past three years , -24% over the past five years , and 6% over the past ten years .
